Analysts' Recent Ratings Updates for Arrowhead Pharmaceuticals


They now have a $13.00 price target on the stock. They wrote, ": We are reiterating our Overweight rating and $13 PT for the completed enrollment of the Phase 1 trial of ARO-AAT for the treatment of Alpha-1 liver disease.



from Biotech News